Questions

239. Deputy Ken O'Flynn asked the Minister for Health if her Department or the HSE has assessed the case for a national osteoporosis screening programme, including DEXA scanning for women over 50 years-of-age; if the matter has been referred to the National Screening Advisory Committee for consideration; and if she will make a statement on the matter. [74790/26]

621. Deputy Ken O'Flynn asked the Minister for Health to list each public hospital or facility currently providing mole mapping, total body photography or dermatoscopic surveillance for patients with a previous melanoma diagnosis; the current waiting time at each; whether patients from the Cork and Kerry region may be referred to each; and if she will make a statement on the matter. [70291/26]

624. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question Nos. 65821/26, 65822/26 and 65823/26, the number of patients enrolled in the mole mapping and melanoma surveillance service at Cork University Hospital on the date the service ceased; the number transferred to specialist follow up; the number discharged to their GP; the clinical criteria applied in deciding which patients were tra…

636. Deputy Ken O'Flynn asked the Minister for Health the supports available to former Cork University Hospital melanoma surveillance patients who were not transferred to specialist follow up and who cannot afford private mole screening; whether the HSE will fund private surveillance for such patients pending restoration of a public service; and if she will make a statement on the matter. [70295/26]

638. Deputy Ken O'Flynn asked the Minister for Health the date on which the consultant who provided the mole mapping service at Cork University Hospital retired; the date on which the HSE was notified of the retirement; whether a replacement post has been approved, advertised or filled; and if she will make a statement on the matter. [70292/26]

1044. Deputy Ken O'Flynn asked the Minister for Health to detail how screening responsibilities are allocated across public-sector and private-sector actors, including universities, employers, and occupational-health providers, and whether any quality-assurance or regulatory oversight exists for screening conducted outside the HSE. [69973/25]

1045. Deputy Ken O'Flynn asked the Minister for Health whether her Department has reviewed the lessons learned from previous major screening initiatives, including those associated with mpox, measles resurgence in Europe in 2024, Covid-19, and travel-associated viral haemorrhagic fever protocols, and to publish any internal evaluations or recommendations arising. [69974/25]

559. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question Nos. 976 and 977 of 12 November 2025, if she is satisfied that her Department and the HSE do not collect centrally the number and cost of standard lipid profile tests ordered from primary care, in view of the acknowledgement that this information is not held in a national dataset; the way in which she assesses value-for-money in p…

562. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question Nos. 976 and 977 of 12 November 2025, the estimated annual percentage growth in standard lipid profile test volumes across the health service since 2021, in view of the statement that test volumes from all areas, including primary care, have increased by between 10 and 15 percent per year; the way in which this trend has informed …

563. Deputy Ken O'Flynn asked the Minister for Health the estimated annual expenditure on standard lipid profile tests ordered from primary care for each year since 2019, based on available data, including the current estimated average cost range per test where precise figures are not available; the reasons for variation in cost per test between regions or providers; and her plans to reduce unwarranted variation and …